Search research articles
Contact Us
Filters
Showing results (541-550 of 692) with videos related to
Page
of 70
Sort By:
Cancer Research
|
November 21, 2000
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
L C Amler, D B Agus, C LeDuc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2019
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 7, 2012
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building
Eric A Sherer, Mark E Sale, Bruce G Pollock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, et al.
JAMA Oncology
|
June 5, 2016
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I Scher, David Lu, Nicole A Schreiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
Dana E Rathkopf, Michael J Morris, Josef J Fox, et al.
European Urology
|
September 19, 2022
Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer
Ethan S Barnett, Nikolaus Schultz, Konrad H Stopsack, et al.
Cancer Research
|
August 21, 2020
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer
Joseph D Schonhoft, Jimmy L Zhao, Adam Jendrisak, et al.
Cancer Chemotherapy and Pharmacology
|
November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Page
of 70
Search research articles
Search
Showing results (541-550 of 692) with videos related to
Sort By:
Page
of 70
Cancer Research
|
November 21, 2000
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
L C Amler, D B Agus, C LeDuc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2019
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 7, 2012
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building
Eric A Sherer, Mark E Sale, Bruce G Pollock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, et al.
JAMA Oncology
|
June 5, 2016
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I Scher, David Lu, Nicole A Schreiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
Dana E Rathkopf, Michael J Morris, Josef J Fox, et al.
European Urology
|
September 19, 2022
Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer
Ethan S Barnett, Nikolaus Schultz, Konrad H Stopsack, et al.
Cancer Research
|
August 21, 2020
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer
Joseph D Schonhoft, Jimmy L Zhao, Adam Jendrisak, et al.
Cancer Chemotherapy and Pharmacology
|
November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Page
of 70